Literature DB >> 8711642

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

J N Pande1, S P Singh, G C Khilnani, S Khilnani, R K Tandon.   

Abstract

BACKGROUND: Several risk factors for the development of hepatotoxicity during short course antituberculosis therapy have been suggested. A case-control study was undertaken to assess the role of age, sex, disease extent, nutritional status, past history of liver disease, infection with hepatitis viruses, acetylator status, and high alcohol intake as risk factors in the development of hepatotoxicity in patients with pulmonary tuberculosis receiving antituberculosis treatment.
METHODS: The cases comprised 86 consecutive patients who were diagnosed as having hepatitis induced by antituberculosis drugs and who were negative for any of the hepatitis markers (HAV-IgM, HBsAg, HBc-IgM, and anti-HCV). The control group comprised 406 consecutive patients attending the chest clinic who completed antituberculosis treatment without developing hepatitis. The variables analysed were age, sex, body mass index (BMI), history of high alcohol intake, radiological extent of the disease, acetylator status, and serum proteins.
RESULTS: The cases were older and their serum albumin levels were lower than in the control group. High alcohol intake was more common among the cases, they had more extensive disease radiologically, and the proportion of slow acetylators was higher. No differences were observed between the two groups in the other risk factors analysed.
CONCLUSIONS: Of the various risk factors analysed, only advanced age, hypoalbuminaemia, high alcohol intake, slow acetylator phenotype, and extensive disease were risk factors for the development of hepatotoxicity. The risk of hepatitis in the presence of one or more of these risk factors may be increased.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8711642      PMCID: PMC473016          DOI: 10.1136/thx.51.2.132

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Hepatitis cases in isoniazid treated groups and in a control group.

Authors:  N Riska
Journal:  Bull Int Union Tuberc       Date:  1976

2.  Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.

Authors:  J R Mitchell; U P Thorgeirsson; M Black; J A Timbrell; W R Snodgrass; W Z Potter; H R Jollow; H R Keiser
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

3.  Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.

Authors:  P Gurumurthy; M S Krishnamurthy; O Nazareth; R Parthasarathy; G R Sarma; P R Somasundaram; S P Tripathy; G A Ellard
Journal:  Am Rev Respir Dis       Date:  1984-01

4.  Isoniazid preventive therapy: Retrospect and prospect.

Authors:  L A Dash; G W Comstock; J P Flynn
Journal:  Am Rev Respir Dis       Date:  1980-06

5.  Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial.

Authors:  D E Snider; M W Long; F S Cross; L S Farer
Journal:  Am Rev Respir Dis       Date:  1984-04

6.  Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.

Authors:  A K Dutt; D Moers; W W Stead
Journal:  Am J Med       Date:  1984-08       Impact factor: 4.965

7.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors:  J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

Review 8.  The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.

Authors:  D J Girling
Journal:  Tubercle       Date:  1978-03

9.  Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid.

Authors:  K V Rao; D A Mitchison; N G Nair; K Prema; S P Tripathy
Journal:  Br Med J       Date:  1970-08-29

10.  Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.

Authors:  C Grönhagen-Riska; P E Hellstrom; B Fröseth
Journal:  Am Rev Respir Dis       Date:  1978-09
View more
  49 in total

Review 1.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

2.  Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers.

Authors:  Lara Dakhoul; Marwan Ghabril; Jiezhun Gu; Victor Navarro; Naga Chalasani; Jose Serrano
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-03       Impact factor: 11.382

3.  Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.

Authors:  Arunava Saha; Margaret Shanthi F X; Blessed Winston A; Saibal Das; Aniket Kumar; Joy S Michael; T Balamugesh
Journal:  J Prim Care Community Health       Date:  2016-04-07

4.  Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.

Authors:  A C Anand; A K Seth; M Paul; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Isoniazid hepatotoxicity requiring liver transplantation.

Authors:  Edward Sheen; Robert J Huang; Lindsay A Uribe; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

Review 6.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.

Authors:  Hoda A Makhlouf; Ahmed Helmy; Ehab Fawzy; Madiha El-Attar; Hebat Alla G Rashed
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

8.  Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review.

Authors:  Fahmi Yousef Khan; Fatima Rasoul
Journal:  Indian J Crit Care Med       Date:  2010-04

9.  Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.

Authors:  Yuag-Meng Liu; Yu-Jen Cheng; Yu-Lin Li; Chun-Eng Liu; Wu-Huei Hsu
Journal:  Lung       Date:  2013-11-30       Impact factor: 2.584

10.  Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

Authors:  Yin Yin Xia; Dai Yu Hu; Fei Ying Liu; Xiao Meng Wang; Yan Li Yuan; De Hua Tu; Yi Xin Chen; Lin Zhou; Li Zhen Zhu; Wei Wei Gao; Hong Yuan Wang; Da Fang Chen; Li Yang; Ping Ping He; Xiao Ting Li; Ying Jian He; Feng Sun; Si Yan Zhan
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.